Study Design
ESSENTIAL HYPERTENSION
The data that support the findings of this study are available from Novartis AG upon reasonable request.This post hoc analysis used data from a multicenter, randomized, double‐blind, parallel‐group study comparing the BP‐lowering effects of sacubitril/valsartan and olmesartan in Japanese patients with mild‐to‐moderate essential hypertension (NCT01599104), conducted from June 2012 to April 2013.